159 related articles for article (PubMed ID: 38032036)
1. Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients.
Xiao J; Gao G; Ding Y; Li J; Gao C; Xu Q; Wu L; Liang H; Ni L; Wang F; Duan Y; Yang D; Zhao H
Chin Med J (Engl); 2023 Dec; 136(24):2931-2937. PubMed ID: 38032036
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
3. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
[TBL] [Abstract][Full Text] [Related]
4. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
[TBL] [Abstract][Full Text] [Related]
5. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
[TBL] [Abstract][Full Text] [Related]
6. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
[TBL] [Abstract][Full Text] [Related]
7. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione SA; Cherian SM; Özdener AE
J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China.
Kong L; Xie X; Fu Y; Gan L; Yang X; Ma S; Long H
Immun Inflamm Dis; 2023 Aug; 11(8):e974. PubMed ID: 37647435
[TBL] [Abstract][Full Text] [Related]
9. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Podzamczer D; Imaz A; Lopez-Lirola A; Knobel H; Masiá M; Fanciulli C; Hernández C; Lagarde M; Gutierrez A; Curran A; Morano L; Montero-Alonso M; Troya J; Rigo R; Casadellà M; Navarro-Alcaraz A; Ardila F; Parera M; Bernal E; Echeverria P; Estrada V; Hidalgo-Tenorio C; Macias J; Prieto P; Portilla J; Valencia E; Vivancos MJ; Rivero A
J Antimicrob Chemother; 2023 Nov; 78(11):2696-2701. PubMed ID: 37725999
[TBL] [Abstract][Full Text] [Related]
10. Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain.
Torralba M; Rodríguez G; González Gasca FJ; Cuadra F; Barberá J; Geijo P; Silva A; García MI; Ostaiza MA; García Pérez AM; Arroyo E; Larrubia JR; Gutiérrez A; Porras ML; Calvo Sánchez H; Peña-Asensio J; Arias JG; Mendoza I
Ann Pharmacother; 2024 Feb; 58(2):140-147. PubMed ID: 37131300
[TBL] [Abstract][Full Text] [Related]
11. Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Tsai MS; Sun HY; Chen CP; Lee CH; Lee CY; Liu CE; Tang HJ; Hung TC; Li CW; Lee YT; Liou BH; Yang CJ; Hung CC;
Int J Infect Dis; 2023 Jan; 126():39-47. PubMed ID: 36384186
[TBL] [Abstract][Full Text] [Related]
12. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Hodder S; Squires K; Kityo C; Hagins D; Avihingsanon A; Kido A; Jiang S; Kulkarni R; Cheng A; Cao H
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):209-213. PubMed ID: 29481486
[TBL] [Abstract][Full Text] [Related]
14. Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
Rotea-Salvo S; Martínez-Pradeda A; Fernández-Oliveira C; Giménez-Arufe V; Balboa-Barreiro V; Margusino-Framiñán L; Mena-De-Cea Á; Vázquez-Rodríguez P; Castro-Iglesias Á; López-Calvo S; Martín-Herranz I; Míguez-Rey E; Cid-Silva P
Eur J Hosp Pharm; 2023 Jul; 30(4):221-226. PubMed ID: 34649965
[TBL] [Abstract][Full Text] [Related]
15. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Salama E; Hill L; Patel N; Best BM; Momper JD
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):389-392. PubMed ID: 34285156
[TBL] [Abstract][Full Text] [Related]
16. Changes in blood lipid levels and influencing factors among treatment-naïve adult male HIV/AIDS patients following BIC/FTC/TAF vs . 3TC+EFV+TDF.
Wang X; Liu A; Li Z; Zhang H; Wu RE; Shao Y; Li J; Ye J; Liu W; Sun L
Chin Med J (Engl); 2024 Jun; 137(12):1447-1452. PubMed ID: 38816366
[TBL] [Abstract][Full Text] [Related]
17. Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
DeKoven S; Naccarato M; Brumme CJ; Tan DHS
HIV Med; 2023 Nov; 24(11):1137-1143. PubMed ID: 37317505
[TBL] [Abstract][Full Text] [Related]
18. Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study.
Emond B; Rossi C; Côté-Sergent A; Dunn K; Lefebvre P; Lafeuille MH; Donga P
J Health Econ Outcomes Res; 2021 Jun; 8(1):88-98. PubMed ID: 34179212
[No Abstract] [Full Text] [Related]
19. Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
Jing C; Wei T; Ning W; Fang Z; Gang X; Xingzhi W; Guoqiang Z; Min W
BMC Infect Dis; 2023 Jun; 23(1):396. PubMed ID: 37308847
[TBL] [Abstract][Full Text] [Related]
20. Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide.
Hsu JY; Sun HY; Chen LY; Chang SY; Chuang YC; Huang YS; Su YC; Liu WC; Hung CC
J Glob Antimicrob Resist; 2024 Mar; 36():426-435. PubMed ID: 37923129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
